Microfluidic synthesis systems for continuous liposome formation and active drug loading

This technology uses microfluidic channels to continuously form liposomes and actively load them with drugs through a transmembrane gradient, enabling efficient high-throughput production.

Background

The field of advanced drug delivery and nanomedicine has witnessed growing interest as researchers strive to improve the precision and efficiency of therapeutic treatments. With an increasing demand for targeted delivery systems that can encapsulate and release pharmaceutical agents in a controlled manner, the emphasis has shifted toward developing robust mechanisms that can perform reliably under continuous production settings. The need arises from a desire to reduce side effects, enhance drug stability, and achieve personalized therapy through improved formulation methods that maintain consistent quality across production batches.

Current approaches, however, face significant issues such as limited scalability, inconsistent product uniformity, and inefficient drug encapsulation processes. Traditional methods often involve batch processing techniques that struggle to produce uniformly sized vesicles and fail to maintain precise gradients essential for optimal drug loading. Moreover, the multi-step processes require complex setups that make quality control and reproducibility challenging, resulting in higher costs and slower production cycles. This creates an urgent need for novel solutions capable of meeting the rigorous demands of modern pharmaceutical manufacturing.

Technology

This technology employs microfluidic systems to continuously produce and load liposomal carriers for therapeutic agents. It features a dedicated formation region where a group of liposomes is generated under a controlled, continuous flow process. Downstream, a microdialysis section establishes a transmembrane gradient that actively facilitates the loading of drugs into the liposomes. Additionally, high aspect ratio microchannels contribute to high throughput, ensuring a consistent and scalable production process suited for large-volume applications.

The approach stands out by integrating the creation of liposomes with their subsequent drug loading in a seamless, one-step continuous process. This integration reduces the need for multiple, complex processing steps typically required in traditional batch methods. The design’s precise control of fluid mixing leads to uniform liposome size and improved drug encapsulation efficiency. As a result, the system delivers enhanced reproducibility and reliability, making it a promising solution for efficient and consistent therapeutic delivery.

Benefits

  • Enhanced control over liposome formation and drug encapsulation through continuous flow synthesis.
  • Efficient active loading of drugs using a transmembrane gradient established by the microdialysis region.
  • High-throughput production enabled by high aspect ratio microchannels.
  • Scalable and reproducible manufacturing process for liposomes.

Applications

  • Pharmaceutical liposome production
  • Active drug encapsulation system
  • Continuous flow synthesis device

Additional info

A microfluidic apparatus enables continuous flow synthesis and active drug encapsulation in liposomal formulations. It features a dedicated liposome formation module and an adjacent microdialysis module that establishes a transmembrane gradient to facilitate active loading. High aspect ratio microchannels ensure high throughput production with precise control over reaction conditions.

PUBLICATIONS

Microfluidic-enabled liposomes elucidate size-dependent transdermal transport. PLoS One. 2014 Mar 21;9(3)

High-Throughput Continuous Flow Production of Nanoscale Liposomes by Microfluidic Vertical Flow Focusing. Small. 2015 Nov 18;11(43):5790-9

Microfluidic synthesis of PEG- and folate-conjugated liposomes for one-step formation of targeted stealth nanocarriers. Pharm Res. 2013 Jun;30(6):1597-607

Microfluidic remote loading for rapid single-step liposomal drug preparation. Lab Chip. 2014 Sep 7;14(17):3359-67